Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -10 of 12
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
9/29/2008
 
First Published:
2/26/2008
1.
Phase I/II Study of Reduced-Intensity Preparative Regimen Comprising Fludarabine, Busulfan, and Alemtuzumab Followed By Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematological Malignancies or Other Diseases
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Active
70 and under
Other
BCM-H-19386
BCM-FAB, H 19386, NCT00625144
Last Modified:
5/22/2008
 
First Published:
2/1/2008
2.
Phase I/II Pilot Study of WT-1 Peptide-Loaded Allogeneic Dendritic Cell Vaccine and Donor Lymphocyte Infusion in Patients With WT1-Expressing Progressive or Relapsed Hematologic Malignancies After Prior Allogeneic Stem Cell Transplantation
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Biomarker/Laboratory analysis, Treatment
Active
1 to 75
NCI
NCI-08-C-0051
08-C-0051, NCI-P06049, NCT00608166
3.
A Multi-Center Phase I Study of AP23573 in Pediatric Patients With Advanced Solid Tumors
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Active
1 to 17
Other
SUN08-01
NCT00704054
Last Modified:
5/21/2008
 
First Published:
12/20/2007
4.
Phase II Study of Graft-Versus-Host Prophylaxis Comprising Sirolimus, Tacrolimus, and Anti-Thymocyte Globulin in Patients Undergoing Unrelated-Donor Hematopoietic Cell Transplantation For Hematological Malignancy
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Supportive care, Treatment
Active
2 and over
NCI
CHNMC-06141
06141, NCT00589563
Last Modified:
10/14/2008
 
First Published:
7/24/2008
5.
Phase II Study of Unrelated Donor Umbilical Cord Blood Transplantation Using a Reduced-Intensity Preparative Regimen in Patients With Hematological Malignancies
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
Any age
NCI
FHCRC-2239.00
FHCRC-2239.00, FHCRC-IR-6722, NCT00723099
Last Modified:
9/17/2008
 
First Published:
11/5/2007
6.
Phase I Study of Ipilimumab (Anti-CTLA-4) in Children, Adolescents, and Young Patients With Advanced or Refractory Solid Tumors
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Biomarker/Laboratory analysis, Treatment
Active
3 to 21
NCI
NCI-08-C-0007
08-C-0007, NCI-P6068, 7458, NCT00556881
Last Modified:
5/27/2008
 
First Published:
1/9/2008
7.
Phase I Study of Umbilical Cord Blood (UCB)-Derived CD25+CD4+ T-Regulatory Cell Infusion After Nonmyeloablative UCB Transplantation in Patients With Advanced Hematologic Cancer and Other Disorders
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Active
12 to 70
NCI
UMN-2007LS022
UMN-2007LS022, UMN-MT2006-01, UMN-0701M00303, UMN-12559, UMN-6220-04, NCT00602693
8.
Total Body Irradiation With Fludarabine Followed by Combined UCB Transplants
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Active
14 to 65
Other
7539
NCT00606437
First Published:
5/1/2008
9.
Phase I Study of Autologous or Allogeneic LMP-Specific Cytotoxic T-Lymphocytes in Patients With Epstein-Barr Virus (EBV)-Positive Lymphoma, Lymphoepithelioma, or Severe Chronic Active EBV Infection Syndrome
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Active
Any age
Other
BCM-H-9936-ALCI
H 9936, NCT00671164
10.
Pilot Study of Haploidentical Natural Killer Cell Infusions for Poor Prognosis Non-AML Hematologic Malignancies
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Active
18 and under
Other
NKHEM
NCT00697671
Select All on One Page
1
2
Next >
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute